NCT07636161
PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)
Not Yet Recruiting
PHASE4Ages 18–40InterventionalTreatmentUniversity of MiamiInvestigator-initiated
~30 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Eroxon®tadalafil
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Erectile Functioning
Measured over Baseline to Week 12
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Sonjia Kenya, E.D · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male sex at birth
Age 18-40 years
Diagnosis of type 2 diabetes mellitus
Diagnosis of erectile dysfunction
Currently prescribed tadalafil
Have a sexual partner willing to complete a survey
Ability to provide informed consent
Exclusion
Type 1 diabetes mellitus
Severe psychiatric illness that would impair participation
Use of nitrates or contraindications to sexual activity
Known allergy to Eroxon® gel components
Participation in another interventional sexual health study
What this trial measures
- Change in Erectile FunctioningBaseline to Week 12
Erectile function assessed using the International Index of Erectile Function-5 (IIEF-5), a validated 5-item patient-reported questionnaire. Total scores range from 5 to 25, with higher scores indicating better erectile function.